[ad_1]
Dis-Chem Pharmacies has confirmed Competition Court approval for the Baby City acquisition, along with three other transactions that it says will further the group’s position as a key provider of integrated primary health care services.
The company said that on November 20, 2020, it received unconditional approval from the Competition Court for the Baby City acquisition.
The effective date of the transaction, on which Dis-Chem will acquire 100% of Baby City, will be January 1, 2021.
“Both Medicare and Dis-Chem are committed to providing a unique and unmatched healthcare experience, with convenience, excellent customer service and value at the core of the brand promise.
“The transaction will also give us access to new markets, as many Medicare stores are in geographies where Dis-Chem is currently under-represented,” said Dis-Chem CEO Ivan Saltzman.
He said Dis-Chem has identified synergies that can be extracted quickly and efficiently. These include the integration of Medicare pharmacies into Dis-Chem’s current supply chain, and CJ Distribution offers more extensive services to pharmacies.
There is great potential to extend Dis-Chem’s loyalty and partner offering, which currently comprises more than 5.7 million members with access to multiple value enhancing partners, to Medicare customers, driving increased frequency of buyers and larger baskets of customers, the group said.
He said the high penetration of pharmacy clinics will expand the coverage of Dis-Chem’s clinic network, which supports its primary care ambitions.
Aligned with the announcement of Medicare is the acquisition of Healthforce.
“Faced with a changing landscape of primary healthcare, Healthforce, through its nurse-led clinical management software, presents Dis-Chem with an investment in an asset that drives its strategic goals of being at the forefront of innovation in healthcare. provision of quality primary services. watch out.
“In addition to the central clinic management capability, Healthforce provides the platform for Dis-Chem to introduce an integrated primary care solution spanning the dispensary and clinic, placing the patient at the epicenter of Dis’s healthcare experience. -Chem, ”said the group.
He said that while Healthforce will operate independently of Dis-Chem, Saltzman said both parties share the vision of enabling a national network of advanced primary care providers.
Healthforce will continue to invest in the development of its solutions, making these advances available to a growing network of independent pharmacies and clinics.
The acquisition of Medicare remains subject to conditions precedent, including approval by the competition authorities.
Meanwhile, Kaelo’s investment will further expand Dis-Chem’s presence in the integrated primary care arena by providing deeper access to quality, affordable healthcare.
“Both Dis-Chem and Kaelo are committed to playing a leadership role in universal access to quality, affordable private primary health care. With the public health care system overwhelmed and private health care out of reach for many, the opportunity for quality, affordable primary health insurance is considerable, ”said Saltzman.
“This acquisition builds on current and past investments and acquisitions, which combined well position Dis-Chem to increase delivery of care in a rapidly evolving primary care landscape.”
The expected effective date of the transaction will be May 1, 2021, subject to approval by the Competition Court.
Read: Dis-Chem is buying Baby City for R430 million
[ad_2]
